News for Sangamo Therapeutics, Inc. (GBY.DE)

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full

We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a look at where Sangamo Therapeutics Inc.

PR NewswireNEW YORK, Jan. 2, 2025 NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeuti

Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (”œSangamo” or the ”œCompany”) (NASDAQ: [url="]SGMO[/ur

Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended the two companies’ partnership to develop a new gene therapy to treat hemophilia A. Sangamo is considering “all options” to continue developing the drug, including finding a new partner, the company said in a statement Monday.…

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.07%

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.26% to 42,461.52 wh...

U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.05% to 42,554.24...

Sangamo Therapeutics Inc. (SMO), a genomic medicine company, experienced a major setback as Pfizer Inc. (PFE) terminated their collaboration on a groundbreaking gene therapy for hemophilia A. The abrupt end to this partnership triggered Sangamo’s largest single-day share drop in more than 15 years. The decision came unexpectedly, with Sangamo's…

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 0.2% on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% ...

On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE). Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new colla

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday. Shares of Sangamo Therapeutics, Inc. SGMO fell sharp...

U.K.-based Aptorum Group Limited (APM) is up over 329 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of Cemtrex, Inc. CETX rose sharply in today's pre-market trading after the company posted stronger-than-expected sales for the fourth quarter, reporting ...

U.S. stock futures were trading higher on Tuesday following Monday's selloff. All four index futures rose in trade.

U.S. stock futures down, investors eye EHang, Sangamo, Cemtrex, CompoSecure, Ambow. Check out Benzinga's premarket coverage & top tech stocks to watch.

Shares of Sangamo Therapeutics, Inc. SGMO rose sharply in today's pre-market trading. Astellas and Sangamo Therapeutics disclosed Capsid license agreement to d...

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday. Shares of Tesla, Inc. TSLA rose sharply during Monday's session after We...

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Tuesday. Shares of The J. M. Smucker Company SJM rose sharply during Tuesday's...